


Edited by
Md Faiyazuddin, Hasan Ali, Md Akbar
and Babar Iqbal

LIPIDS IN PULMONARY DRUG DELIVERY



LIPIDS IN PULMONARY DRUG DELIVERY

This page intentionally left blank

LIPIDS IN PULMONARY DRUG DELIVERY

Edited by

MD FAIYAZUDDIN

School of Pharmacy, Al-Karim University, Katihar, Bihar, India

HASAN ALI

Department of Pharmacy, Meerut Institute of Technology, Meerut, Uttar Pradesh, India

MD AKBAR

School of Pharmacy, Al-Karim University, Katihar, Bihar, India

BABAR IQBAL

Formulation and Development, Unicare India Ltd, Greater Noida, Uttar Pradesh, India



ELSEVIER



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-443-22374-7

For information on all Academic Press publications visit our website at
<https://www.elsevier.com/books-and-journals>

Publisher: Mica Haley
Acquisitions Editor: Andre Wolff
Editorial Project Manager: Soumya Yadav
Production Project Manager: Fahmida Sultana
Cover Designer: Christian Bilbow

Typeset by TNQ Technologies



Dedication

This book is dedicated to my beloved grandfather, the late Md. Shamshuddin Saheb, who departed from this world far too soon. To me, he was the whole world—a beacon of love, humility, compassion, and understanding. His family-oriented nature made him the heart of our family, and his absence leaves a profound void in my life. I will miss you deeply, Grandpa. I pray to Allah (SWT) to bless your soul and grant you Jannatul-Firdous (the highest level of heaven).

“O Allah, forgive and have mercy upon him, excuse him and pardon him, and make honorable his reception. Expand his entry, cleanse him with water, snow, and ice, and purify him of sin as a white robe is purified of filth. Exchange his home for a better home. Admit him into the Garden; protect him from the punishment of the grave and the torment of the Fire.”

—*Professor (Dr.) Md. Faiyazuddin*

This page intentionally left blank

Contents

Contributors xiii

About the editors xvii

Preface xix

Acknowledgments xxi

1. Lipid nanotechnology

Hasan Ali, Md Faiyazuddin and Md Akbar

1. Introduction 1
 2. Lipids 2
 3. Lipid nanotechnology 4
 4. Drug delivery based applications 7
 5. Lipid nanofluidics 11
 6. Lipid-based self-assembly structures 12
 7. Lipid nanotechnology: A translational perspective in medicine 13
 8. Challenges 16
 9. Conclusion 16
- References 17

2. Current scenario and challenges of lipid-based nanomedicines for pulmonary drug delivery

Amol D. Gholap, Pankaj R. Khuspe, Md Faiyazuddin, Md Jasim Uddin, Juhi Gupta, Pallavi Kamandar, Deblina D. Bhowmik and Navnath T. Hatvate

1. Introduction 21
2. Lipid-based nanocarriers 23
3. Advantages and challenges of lipid-based nanomedicines 27
4. Challenges in formulation development 29
5. Aspects related to regulation 30
6. Current advancements in lipid-based nanomedicines for delivery to the pulmonary system 31
7. Lipid-based macromolecule nanocarriers 32
8. Impact of transformation on the delivery of pulmonary drugs 33

9. Lipid-based nanocarriers' function 34
 10. Patient acceptance and compliance: Advancing personalized healthcare 36
 11. Aspects of pharmacoeconomics 37
 12. Conclusion 40
- References 40

3. Effect of environment of the respiratory tract on nanomedicine drug delivery

Mohammad Imran, Arshi Chaudhary, Masood Ali, Saurav Kumar Jha and Yousuf Mohammed

1. Introduction 49
 2. Impact of pulmonary environment on the delivery of APIs via nanoparticulate systems 50
 3. Innovative nanoparticulate system for efficient pulmonary delivery of drugs 55
 4. Novel polymeric excipients to enhance pulmonary delivery 59
 5. Extracellular vesicles as a delivery platform for pulmonary drug delivery 60
 6. Biomedically engineered devices utilised for pulmonary drug delivery 60
 7. Progress made on pulmonary delivery of vaccines 61
 8. Conclusion 63
- References 64

4. Aerodynamics and deposition of lipid-based nanocarriers in the lungs

Mohammad Intakhab Alam, Hasan Ali and Md Akbar

1. Introduction 69
 2. Aerosolization of drug carriers in lungs 70
 3. Aerodynamics of lipid nanocarriers in lungs 74
 4. Deposition of lipid nanocarriers 74
 5. Clearance of nanoparticle from pulmonary route 76
 6. Conclusion 81
- References 81

5. Liposome as a versatile carrier for pulmonary drug delivery

Dinesh Kumar, Sonia Gupta, Rajni, Jasmine Kaur Bhatia, Kirri and Md Faiyazuddin

1. Introduction 85
 2. Structure of liposomes 86
 3. Role of carriers in enhancing drug efficacy and targeting of liposomes in pulmonary drug delivery 86
 4. Enhancement of drug efficacy 86
 5. Targeting and drug delivery efficiency 87
 6. Classification of liposome 88
 7. Liposome in pulmonary drug delivery: Mechanism of action 91
 8. Strategies for pulmonary delivery system 92
 9. Physicochemical characterization 93
 10. Particle size 93
 11. Particle morphology 94
 12. In vitro and in vivo evaluation techniques 96
 13. Zeta potential measurement 97
 14. Methods of measurement 98
 15. Advantages of studying cell culture 98
 16. Studies on cell cultures 98
 17. Latest advancement in liposomes 100
 18. Conclusion 100
- References 101

6. Advancements in nanostructured lipid carriers as drug delivery vehicles in the lungs

Babar Iqbal, Kashish Aziz, Nasiruddin Ahmad Farooqui and Ashraf Khan

1. Introduction 105
 2. Nanostructured lipid carriers 106
 3. Optimal conditions for creating NLCs based DDS with lung targeting 108
 4. NLCs based DDS to treat various lung diseases 109
 5. Preclinical safety and efficacy of NLCs for lung targeting 115
 6. Future scope 116
 7. Summary and conclusion 116
- References 117

7. Solid lipid nanoparticles: A potential drug carrier in pulmonary system

Akanksha Lahiri and Balamuralidhara V

1. Introduction 121
 2. Criteria for the use of lipid nanoparticles in pulmonary applications 123
 3. Guidelines for developing SLN-based aerosols for lungs 125
 4. Advantages of SLN after pulmonary administration 126
 5. Conclusion 130
- References 130

8. Insights and applications of nanoemulsions as a drug carrier in lungs

Rupali Sharma, Yashomita Mehta, Kavita Sapra, Shekhar Sharma and Shrestha Sharma

1. Introduction 133
 2. Aspects of nanoemulsion formulation and method of preparation 136
 3. Digestion of nanoemulsions 141
 4. Characterization of nanoemulsions 141
 5. Nanoemulsion for lung cancer therapy 143
 6. Insight and applications of nanoemulsion as a drug carrier in lungs 145
 7. Clinical aspect of nanoemulsions 146
 8. Applications of nanoemulsions in drug delivery 147
 9. Future perspectives 149
- References 149

9. Lipid-based drug delivery for lungs cancer

Mohd Sayeed Shaikh, Rupesh R. Kurhade, Shaikh Shahbaz A. Majeed, Jaiprakash N. Sangshetti and Md Faiyazuddin

1. Introduction 153
2. Challenges of conventional drug therapy and emerging treatments in LC treatment 157
3. Lipid-based drug therapy 160
4. Physicochemical aspects to take into account for effective lipid-based nanocarrier-based pulmonary delivery of anticancer drugs 161

5. Passive, and active targeting for efficient lipid-based nanocarrier-based pulmonary delivery of anticancer drugs 164
 6. Devices for the intrapulmonary administration of lipid-based nanocarrier-loaded anticancer drugs 166
 7. Lipid-based nanocarriers for LC treatment 168
 8. Challenges of lipid-based drug therapy in LC treatment 174
 9. Pros and cons of lipid-based drug therapy in LC treatment 175
 10. Conclusion 176
- References 176

10. Exploring the state-of-art of lipid nanomedicines for obstructive pulmonary diseases

Himanshu Sharma, Monika Kaushik, Sumel Ashique, Anas Islam, Subhajit Mandal and Naheed Mojgani

1. Introduction 191
 2. Physiology of the respiratory system 194
 3. Lipid-based nanocarriers: An overview 195
 4. Role of lipid-based nanocarriers in managing OPDs 209
 5. Mechanisms of targeted drug delivery 211
 6. Recent advancements in design and formulation 214
 7. Safety consideration and toxicity profile 218
 8. Future perspectives 220
 9. Conclusion 221
- References 223

11. Lipid-based drug delivery for pulmonary microbial infections

Pooja Jain, Foziyah Zakir, Manvi Singh, Mamta Bishnoi, Bushra Ahmad and Zeenat Iqbal

1. Introduction 233
2. Brief about pulmonary microbial infections 235
3. Types of lipid-based systems for pulmonary delivery 235
4. Nanoemulsion and microemulsions 240
5. Liposomes 241
6. Solid lipid nanoparticles (SLN) 241
7. Polymeric nanoparticles 241
8. Nanomicelles 242

9. Formulation strategies and limitations of lipid-based drug delivery systems 242
 10. Efficiency of lipid-based delivery system 242
 11. Device competency 246
 12. Patient compliance 246
 13. Clearance and bioavailability of lipid-based delivery system 247
 14. Mucociliary and alveolar macrophage clearance 247
 15. Enzymatic degradation 248
 16. Conclusion 249
- References 249

12. Lipid-based drug delivery for systemic effect through pulmonary route of administration

Md Jasim Uddin, Md Faiyazuddin, Amol D. Gholap, Safiya Mohammed Saeed, Samiha Binte Sadiq and Ismat Ara Chowdhury Koly

1. Introduction 255
 2. Techniques involved with lipid-based pulmonary drug delivery system 262
 3. Lipid-based particles for pulmonary drug delivery 271
 4. Lipid-based pulmonary drug delivery devices 280
 5. FDA-approved treatments for different diseases via pulmonary route 283
 6. Challenges in development of pulmonary drug delivery system 288
 7. Discussion 291
 8. Conclusion 291
- References 292

13. Biofate of lipid-based nanomedicine after pulmonary administration

Shrestha Sharma, Suman Khurana, Rupali Sharma, Syed Arman Rabbani and Himanshu Shrivastava

1. Introduction 301
2. Physicochemical considerations for pulmonary drug delivery 302
3. Lipid-based nanomedicine for pulmonary delivery 304
4. Biofate of lipid-based nanomedicine after pulmonary administration 311

5. Challenges of inhaled nanomedicine and design considerations 313
6. Conclusion and future perspectives 315
- References 316
- 14. Surface modification of lipid based drug delivery for lungs**
- S. Sharmila, C. Karthikeyan, Md Faiyazuddin, S. Arthi, Ushasi Das, Shayan Maqsood, Ananya Chakraborty and S. Gowri
1. Introduction 319
 2. Nanoparticles based therapeutic approaches 322
 3. Current applications of nanocarriers 323
 4. Lipid-based nanocarriers 324
 5. Imaging modalities used 329
 6. Nanodiagnosics 330
 7. In vivo examination 330
 8. Conclusion 331
- References 332
- 15. Evaluation of lipid-based formulation for pulmonary delivery**
- Mazen Al-Mohaya, Yavuz Selim Çelik and Burcu Demiralp
1. Introduction 337
 2. Physicochemical characterization 337
 3. Encapsulation efficiency 340
 4. Drug loading 342
 5. In vitro studies 342
 6. Toxicity analysis 343
 7. In vivo studies 345
 8. In vivo in vitro correlation studies 347
 9. In silico studies 348
- References 349
- 16. Physicochemical stability of lipid based nanocarriers in aerosol formulation**
- Pankaj Kumar Sharma, Monika Targotra, Akanksha Sharma, Nidhi Bhatt, Meenakshi Kanwar Chauhan and Yasmin Sultana
1. Introduction 353
 2. Colloidal stability of nanoformulation 355
 3. Phase stability 359
 4. Storage stability 364
 5. How to overcome the instability problems in aerosols 365
6. Conclusion 367
- References 367
- 17. Translation of lipid based formulation for pulmonary drug delivery system: Clinical status**
- Kalra Mohini, Thakur Shabnam, Rupali Sharma and Shrestha Sharma
1. Introduction 371
 2. LBFs for pulmonary drug delivery 373
 3. Preclinical studies of LBFS for pulmonary drug delivery 375
 4. Clinical studies of LBFS for pulmonary drug delivery 385
 5. Future directions and challenges of LBFS for pulmonary drug delivery 387
 6. Conclusion 392
 7. Research implications 393
- References 393
- 18. Regulatory aspects of lipid-based nanomedicine for pulmonary applications**
- Faraat Ali, Kumari Neha, Anam Ilyas, Varisha Anjum and Hasan Ali
1. Introduction 397
 2. Key considerations 398
 3. Regulatory stance on developing nanomedicines 399
 4. Worldwide regulatory bodies 401
 5. Novel approved lipid based nanomedicine for pulmonary application 404
 6. Challenges and future directions 406
 7. Conclusion 407
- References 407
- 19. Lipid-based vaccines against viruses including COVID-19**
- Amol D. Gholap, Pankaj R. Khuspe, Md Faiyazuddin, Md Jasim Uddin, Deblina D. Bhowmik, Rushikesh P. Said, Kalyani S. Sonawane, Swapnali Parit and Navnath T. Hatvate
1. Introduction 409
 2. Types of lipids used in vaccine development 412

3. Lipid-based adjuvants and their role in enhancing vaccine efficacy 413
 4. Challenges and considerations 420
 5. Case studies 421
 6. Preclinical and clinical trials status 422
 7. Future prospective and directions 424
 8. Conclusion 425
- References 426

20. Lipid-based nanocarriers in management of cystic fibrosis: A pulmonary complication

Shubhrat Maheshwari, Aditya Singh, Sudarshan Singh, Bhupendra Prajapati and Pavan Kumar

1. Introduction 435
 2. Pathophysiology/epidemiology and causes of cystic fibrosis 436
 3. Lipid-based nanocarriers current drug delivery system 437
 4. Current therapies carrier-based drug delivery in treatment of cystic fibrosis 440
 5. Conclusions and future remarks 445
- References 445

21. Pulmonary drug delivery of lipid-based formulations via nebulizers

Anas Islam, Ambareen Fatima Ahmed, Widhilika Singh, Usama Ahmad, Asad Ahmad, Mohd Muazzam Khan and Md Faiyazuddin

1. Introduction 449
2. Lipid-based nebulizers 453

3. Formulation development 456
 4. Nebulizer performance 468
 5. Clinical applications 472
 6. Safety and regulatory considerations 478
 7. Conclusion 480
- References 481
- Further reading 490

22. Lipid-based peptide and gene delivery to lungs

Olivia Sen, Sreejan Manna, Ria Dutta and Sougata Jana

1. Introduction 491
 2. Ideal characteristics of a lung-specific drug delivery system 493
 3. Lipids as drug carrier 494
 4. Applications of lipids in lungs specific peptide and gene delivery 496
 5. Conclusion 505
- References 505

Index 511

Pulmonary drug delivery of lipid-based formulations via nebulizers

*Anas Islam^{1,2}, Ambareen Fatima Ahmed¹,
Widhilika Singh^{1,3}, Usama Ahmad³, Asad Ahmad³,
Mohd Muazzam Khan² and Md Faiyazuddin⁴*

¹School of Pharmaceutical Sciences, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India; ²Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India; ³Department of Pharmaceutics, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India; ⁴School of Pharmacy, Al-Karim University, Katihar, Bihar, India

1. Introduction

Medical devices are any goods or equipment that are used to identify an illness or other conditions, to treat, cure, or prevent disease, according to the Food and Drug Administration (FDA) [1]. The Center for Medical Devices and Radiological Health (CDRH) of the FDA is responsible for categorizing, upholding, regulating, and authorizing these devices for use in humans. These gadgets are categorized according to their specialty or intended usage. Such devices are of considerable use in monitoring health, providing care, mitigating mobility, helping in surgical procedures, improving aesthetics, etc. One such broad category of medical devices is respiratory devices. These devices aid in breathing, ventilation, and oxygenation and can be used in home or clinical settings. Respiratory devices encompass those that help deliver drugs and/or support life. These devices include continuous ventilators, bilevel positive airway pressure machines (BPAP), continuous positive airway pressure machines (CPAP), and aerosol delivery devices. Aerosol delivery devices include metered dose inhalers, dry powder inhalers, and nebulizers [2].

1.1 Nebulizers

A nebulizer is a device that holds liquid medication and converts it into an aerosol by using a small air compressor that is delivered directly to the patient for breathing. A nebulizer essentially consists of a drug reservoir with a lid, an air compressor, a mouthpiece/face mask, and tubing. The air compressor is attached to the drug reservoir through tubing over which a lid is placed that connects to a mouthpiece/face mask. The air compressor converts the air to a fine mist that carries the drug from the reservoir through tubing to be inhaled by the patient. With the use of a nebulizer, a drug is directly delivered to the respiratory system. This delivery method if used properly helps the drug reach both the small and large airways and increases the efficacy of the treatment. Nebulizers are often used by children, old persons, very ill people, or those who find it difficult to use an inhaler [3].

Nebulizers have been developed in design to suit the needs of the treatment and type of drug to be delivered, reduce wastage of drugs, and increase the effectiveness of the therapy. Consequently, there are different types of nebulizers available including (pneumatic) jet nebulizers (JNs), ultrasonic nebulizers (USN), and vibrating mesh nebulizers (VMNs). JNs are further divided into constant-output nebulizers (CON), breath-enhanced nebulizers (BENs), breath-actuated nebulizers (BANs), and dosimetric nebulizers [4,5]. Diverse designs of nebulizers are available for different types as per the manufacturer specifications and thus show different efficacy in delivering the aerosol [6].

1.1.1 Jet nebulizers (JNs)

These nebulizers work on the principle of the venturi effect. The major component of these types of nebulizers is the drug reservoir or the nebulizing chamber that has an inlet for compressed air. The inlet pipe is constricted as it enters the nebulizing chamber. The constricted end has an orifice or the nozzle through which the air comes out. The nozzle has a nozzle cover, placed over the nozzle at a fixed distance creating a capillary. When the air enters this constricted pipe, there is a drop in pressure as it moves out of the orifice or nozzle. This creates a low-pressure area that is distributed with the help of baffles in the nebulizing chamber. Because of the subatmospheric pressure created in the nebulizing chamber, the medication in the liquid or suspension form rises upward toward the orifice by capillary action or the Bernoulli effect and is aerosolized with the help of the air from the compressor. This aerosol accumulates in the upper part of the chamber and can be inhaled through the face mask or a mouthpiece [7]. CON generates aerosol during inhalation and exhalation, thus contributing to the wastage of the drug during the exhalation phase whereas BEN generates aerosol only during the inhalation phase, and during the exhalation phase the gas generating the aerosol returns back to the power gas supply. With dosimetric and BAN, aerosol is released only upon inhalation [8].

1.1.2 Ultrasonic nebulizers (USN)

Developed during the 1960s [9], these nebulizers use ultrasonic waves produced by the vibration of piezoelectric crystals. The high-frequency source is used to generate the ultrasonic waves in the piezoelectric crystals, which are transmitted to the drug solution or suspension directly or through a coupling liquid. These ultrasonic waves produce smaller or larger